

## Navana Pharmaceuticals Ltd.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

## **Dividend Compliance Report (2021-2022)**

	Report Distribution Compliance Report					
	Under Clause (6) of the Directive No. BSEC/CMRR	CD/2021-386/03,dated:14/01/2021				
1	Name of the Issuer/Securities/Mutual Fund	Navana Pharmaceuticals Limited				
2	Particulars of Issuer DP	649				
3	Type of the Dividend (Annual/ Interim) (Put tick mark (a) on the recommended option)	a) Annual √ b) Interim				
4	Whether audited or not for Interim Dividend (Put tick mark (a) on the recommended option)	a) Audited v b) Unaudited				
5	Date of recommendation of Dividend by the Board of Directors/Trustee(Enclose Copy of PSI)	27.10.2022				
6	Whether Dividend recommended other than directors or sponsors or any other classes (Put tick mark (a) on the recommended option)	a) Yes b) No v				
7	Record date for entitlement	28.11.2022				
		a) Cash Dividend: 11%				
8	Rate of Dividend recommendation by the Board of Directors/Trustee	b) Bonus/Stock Dividend:				
9	Dividend recommended-Type (Put tick mark (a) on the recommended option)	a) Cash v b) Stock				
10	Securities/mutual fund traded under which categories (Put tick mark (a) on the recommended option)	a) A b) B c) G d) Nv e) Z				
11	Date of transfer to a separate bank account (pls. mention bank details) or provisional credit of shares/units by CDBL	A) Date of Cash Dividend Transfer: 07.11.2022, Bank: United Commercial Bank Limited, A/C No.0951301000001971, Branch: Corporate				
12	Date of approval of Dividend at AGM	22.12.2022				
13	Rate of Dividend approved at AGM-details at Annexure, (in any change)	a) Cash Dividend: 11%				
14	Date of commencement of disbursement of Cash and Stock dividend	Disbursed to the respective Bank Accounts of the Shareholders' (who are registered as on Record Date i.e. 28.11.2022) linked with their recorded BO number through BEFTN, EFT & Dividend Warrant from 03.01.2023 to 18.01.2023.				
		The remaining un-remitted cash dividends, due to non-availability of BEFTN facilities or error in information have been dispatched by courier services to the respective shareholders' address registered with the Company on 18.01.2023				
15	Mode of disbursement of cash dividend (Put tick mark (a) on the recommended option)	a) BEFTN V B) Bank Transfer V  C) MFC d) Dividend warrant V				





## Navana Pharmaceuticals Ltd.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

		e) Any other mod	de 🔻	
16	Date of completion of disbursement of cash Dividend and Stock Dividend [Enclose Bank statements and Corporate Action processing Report (DP70)]	A) Date of Cash Dividend Transfer: 18.01.2023 B) Date of Credit of Shares/units by CDBL: N/A		
17	Paid-up-capital of the issuer-before corporate action/entitlement	N/A		
8	Numbers of securities/shares outstanding-before corporate actio	a) Cash Dividend TK. 11,81,57,838.70 (Included Tax) b) Bonus/Stock Dividend: N/P		
.9	Total cash in taka or stock (nos. shares) dividend as per corporate declaration			
20	Distribution/disbursement details of Cash & Stock Dividend:	Cash-Net Dividend (Tk.)	Stock (nos.)	Annexures
	A. Mode of Dividend Payment/credit for the concerned year:			
	a) through BEFTN or directly credited to respective BO	3,99,75,244.18		
	B) through Bank Transfer other than entitled BO-Margin Loan			
	C) through Bank Transfer	1,08,01,642.69		
	d) through Mobile Financial Service (MFS)			
	e) through any other mode as approved by Bangladesh Bank	9*		
	f) through transfer to Suspense Account for dematerialized Shares (BO wise detailed with reason should be maintained and submitted)			
	g) through issuance of Dividend warrant/ Cheque or issue of Shares to Suspense Account for Non-dematerialized securities	4,43,14,008.53		
21	Total Dividend paid/credited for the concerned year	9,50,90,895.4		
2	Total unpaid/undistributed Dividend/accrued during the period	99,39,113.61		
23	Total unpaid/undistributed Dividend/accrued as on 1st day of Accounting year (as per Audited Accounts)	N/P	N/P	
24	Transfer to suspense Account for Demate Shares or any other reasons during concerned year	N/P	N/P	
	A. Mode of Dividend Receipts/payment/credit for the previous			
	years:	N/P	N/P	
	a)through BEFTN directly credited to respective BO	N/P	N/P	
	b)through Bank Transfer	N/P	N/P	
	C) through Mobile Financial Service (MFS)	N/P	N/P	
	d) through any other mode as approved by Bangladesh Bank	N/D	N/P	
	(Dividend warrant)	N/P	IN/P	
	e)through transfer to/from Suspense Account for Demate			
	Shares or any other reasons f)through issuance of Dividend Warrant or issue of shares to Suspense Account for non-dematerialized	N/P	N/P	
	securities/shares/units g)transfer of cash or stocks to the fund as prescribed or directed by commission after 3 years or forfeit of share to			
	Suspense Account for non-dematerialized securities	N/P	N/P	
25	Total Dividend paid/credited for previous years:	N/P	N/P	
	Total unpaid/undistributed Dividend for previous years	N/P	N/P	
26	(23+24-25) Taka/Nos			
	(23+24-25) Taka/Nos Grand Total of unpaid/undistributed Dividend (22+26)	N/P	N/P	
27	Grand Total of unpaid/undistributed Dividend (22+26)  Aging of grand Total of unpaid/undistributed Dividend			
26 27 28	Grand Total of unpaid/undistributed Dividend (22+26)	N/P N/P N/P	N/P N/P N/P	





## Navana Pharmaceuticals Ltd.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

N/P	NI/D
IV/P	N/P
N/P	N/P
N/P	N/P
	N/P N/P

Note: Issuer shall maintain BO wise details information for all transfers/credit to suspended Accounts

With reasons and submit along with bank statements and other supporting documents. The issuer shall fill up all the applicable fields.

Reporting Date: January 22, 2023

Authorize Signature with seal (With name & designation)

Joynul Abedin ACS
Deputy General Manager & Company Secretary
Navana Pharmaceuticals Ltd.